Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine

1. A pharmaceutical combination comprising an antibody specifically recognizing CD38 and at least vincristine, wherein said antibody is capable of killing a CD38 + cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC);

wherein said antibody comprises at least one heavy chain comprising three sequential complementarity-determining regions (CDRs) comprising the amino acid sequences of SEQ ID Nos: 13, 81, and 15, and at least one light chain comprising three sequential complemetarity-determining regions (CDRS) comprising the amino acid sequences of SEQ ID NOS: 16, 17, and 18;

and wherein the antibody and vincristine constituents of the combination are physically separate.

2. The combination of claim 1 , wherein said antibody is a humanized antibody.

3. The combination of claim 1 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO: 66, and wherein said light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 62 and 64.

4. A method for treating a hematological cancer in a subject, the method comprising administering the pharmaceutical combination of claim 1 to the subject, thereby treating the hematological cancer in the subject.

5. The method of claim 4 , wherein said antibody is a humanized antibody.

6. The method of claim 4 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO: 66, and wherein said light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 62 and 64.

7. The method of claim 4 , wherein the constituents of the combination are administered simultaneously.

8. The method of claim 4 , wherein the constituents of the combination are administered spaced out over a period of time.